Corporate Banner
Satellite Banner
qPCR
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New IVD Product is Designed to Improve Prevention and Control of GBS in Newborns

Published: Wednesday, March 28, 2012
Last Updated: Wednesday, March 28, 2012
Bookmark and Share
BD MAX™ GBS assay receives FDA clearance and CLIA moderate complexity test categorization.

BD (Becton, Dickinson and Company) has announced that the U.S. Food and Drug Administration (FDA) clearance of the BD MAX™ Group B Streptococcus (GBS) Assay and Clinical Laboratory Improvement Amendments (CLIA) moderate complexity test categorization on the second-generation BD MAX™ System.  The BD MAX GBS Assay is an in vitro diagnostic (IVD) test for detection of GBS DNA in Lim Broth cultures - enabling laboratories to comply with the 2010 CDC guidelines for GBS screening.

The BD MAX GBS Assay is the only automated IVD method for polymerase chain reaction (PCR) detection of GBS from Lim Broth with a moderate complexity test categorization.  The assay provides an easy-to-use, cost-effective method for laboratories seeking access to a molecular method and optimized resource utilization for GBS testing. BD MAX is the first and only automated, bench-top molecular system designed to perform a broad range of molecular testing, offering unmatched flexibility and versatility.

"FDA clearance of the BD MAX GBS Assay on the second-generation BD MAX System moves BD closer to our goal of providing a next-generation molecular testing system designed to offer and accommodate a broad range of assays," said Gregory Meehan, Vice President, BD Diagnostics – Diagnostic Systems, Molecular Diagnostics. "By simplifying the testing for GBS colonization status, the BD MAX GBS Assay can support improved prevention and control of GBS infections in newborns."

GBS is the leading infectious cause of morbidity and mortality among infants in the United States. The Centers for Disease Control and Prevention estimates that in recent years GBS has caused approximately 1,200 cases of early-onset invasive disease per year; approximately 70 percent of cases are among babies born at term (37 weeks gestation or more).  Screening for colonization late in gestation can identify women who are likely to be colonized with GBS at the time of delivery.

According to Meehan, clearance and categorization of the BD MAX GBS Assay as moderate complexity are important milestones. As we work to develop methicillin-resistant Staphylococcus aureus and Clostridium difficile assays in the months ahead, and additional assays in the years ahead, we believe the BD MAX System is well positioned to potentially be a vital resource for the widest possible range of laboratory testing needs.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BD Receives FDA Clearance for Gastroenteritis Test
The FDA-cleared BD MAX™ Enteric Bacterial Panel for use on the BD MAX System.
Monday, May 12, 2014
Scientific News
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Gene Analysis System Could Accelerate Pace of Research on the Space Station
The WetLab-2 system will enable spaceflight genomic studies involving a wide variety of biospecimen types in the unique microgravity environment of space.
Liquid Biopsy for NSCLC
'Liquid biopsy' blood test accurately detects key genetic mutations in most common form of lung cancer, study finds.
Rare DNA Will Have Nowhere To Hide
Two National Institutes of Health grants back Rice University effort to develop new diagnostics.
Seeing Cell to Cell Differences
Seeing differences between individual cells for first time explains symptoms of rare genetic disorders, finds penn study.
Circular RNAs Implicated in Cancer
Circular RNAs – like their protein counterparts – are also affected by genomic rearrangements in cancer, resulting in abnormal fusions.
Know Thy Helicobacter pylori
Non-invasive method for genotyping H.pylori developed.
Zika Test Authorized for Emergency Use
n response to a request from the CDC, the FDA has issued an Emergency Use Authorization (EUA) for a diagnostic tool for Zika virus that will be distributed to qualified laboratories.
Lighting Up Disease-Carrying Mosquitoes
Sandia’s QUASR enables speedy, accurate detection of West Nile and other viruses.
Ultra-Sensitive Test for Cancers, HIV
Test developed that is thousands of times more sensitive than current diagnostics.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!